Developing innovative drugs through the commons Lessons from the DNDi experience
Résumé
In this paper we argue that DNDi, even though it belongs to the family of Product Development Partnerships (PDPs) created at the end of the 20th century, has followed a very particular trajectory, that allows us to characterize it as a distinctive commons in the field of public health. We illustrate this view by focusing on two features: DNDi’s promotion of collaborative platforms and its innovative intellectual property policy.
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|
